{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:49Z","timestamp":1782100189812,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00558-6","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:51:14Z","timestamp":1780300274000},"page":"279-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Ofatumumab in Relapsing Multiple Sclerosis: Comparison of Treatment-Na\u00efve Patients and Switchers in a Multicenter Cohort"],"prefix":"10.1007","volume":"13","author":[{"given":"Vincenzo","family":"Mangialardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Macchitella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Vitobello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Teofilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Lapucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Idini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Iaffaldano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde M.","family":"Inglese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8645-1763","authenticated-orcid":false,"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,31]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378:169\u201380.","journal-title":"N Engl J Med"},{"issue":"9","key":"558_CR2","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"10","author":"H Lassmann","year":"2019","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019;10(9):3116.","journal-title":"Front Immunol"},{"key":"558_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.","journal-title":"Nat Rev Dis Primers"},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm1714","volume":"14","author":"B Obermeier","year":"2008","unstructured":"Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med. 2008;14:688\u201393.","journal-title":"Nat Med"},{"key":"558_CR5","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","volume":"19","author":"R Li","year":"2018","unstructured":"Li R, Patterson KR, Bar-Or A. Reassessing B-cell contributions in multiple sclerosis. Nat Immunol. 2018;19:696\u2013707.","journal-title":"Nat Immunol"},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/imm.13198","volume":"160","author":"T Gharibi","year":"2020","unstructured":"Gharibi T, Babaloo Z, Hosseini A, et al. The role of B cells in the immunopathogenesis of multiple sclerosis. Immunology. 2020;160:325\u201335.","journal-title":"Immunology"},{"key":"558_CR7","volume":"12","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R. B cells in the central nervous system compartment of multiple sclerosis. Front Immunol. 2021;12:676895.","journal-title":"Front Immunol"},{"key":"558_CR8","volume":"229","author":"A Bar-Or","year":"2021","unstructured":"Bar-Or A, Li R. Cellular and molecular mechanisms of action of anti-CD20 therapies in multiple sclerosis. Clin Immunol. 2021;229:108781.","journal-title":"Clin Immunol"},{"key":"558_CR9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N Engl J Med. 2008;358:676\u201388.","journal-title":"N Engl J Med"},{"key":"558_CR10","first-page":"153","volume":"18","author":"X Montalban","year":"2022","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Anti-CD20 therapies in multiple sclerosis: mechanisms and clinical evidence. Nat Rev Neurol. 2022;18:153\u201367.","journal-title":"Nat Rev Neurol"},{"key":"558_CR11","doi-asserted-by":"publisher","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol. 2024;271(4):1515\u201335. https:\/\/doi.org\/10.1007\/s00415-023-12007-3.","DOI":"10.1007\/s00415-023-12007-3"},{"key":"558_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Comi G, Bar-Or A, et al. Ofatumumab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2020;383:546\u201357.","journal-title":"N Engl J Med"},{"key":"558_CR13","first-page":"1532","volume":"29","author":"AH Cross","year":"2023","unstructured":"Cross AH, Cree BAC, Devonshire V, et al. Long-term efficacy and safety of ofatumumab: interim analysis of the ALITHIOS study. Mult Scler. 2023;29:1532\u201347.","journal-title":"Mult Scler"},{"key":"558_CR14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s40120-023-00518-0","volume":"12","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Cree BAC, Sormani MP, et al. Continuous monthly ofatumumab: post hoc integrated analyses from clinical trials. Neurol Ther. 2023;12:429\u201346.","journal-title":"Neurol Ther"},{"key":"558_CR15","first-page":"880","volume":"16","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg S\u00f8rensen P. Evolving concepts in the treatment of multiple sclerosis: early high-efficacy therapy. Lancet Neurol. 2017;16:880\u201391.","journal-title":"Lancet Neurol"},{"key":"558_CR16","first-page":"247","volume":"92","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Pozzilli C, et al. Escalation versus early high-efficacy treatment strategies in relapsing multiple sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:247\u201354.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"558_CR17","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with long-term clinical outcomes in multiple sclerosis. JAMA. 2019;321:1757\u201368.","journal-title":"JAMA"},{"key":"558_CR18","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1007\/s00415-022-11191-y","volume":"269","author":"L Prosperini","year":"2022","unstructured":"Prosperini L, Borriello G, Fantozzi R, et al. Risk of infections associated with anti-CD20 monoclonal antibodies in multiple sclerosis: a real-world multicenter study. J Neurol. 2022;269:6145\u201356.","journal-title":"J Neurol"},{"key":"558_CR19","first-page":"72","volume":"97","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Cohen JA. Transitioning from S1P receptor modulators in multiple sclerosis: rebound, risk, and management strategies. Neurology. 2021;97:72\u201383.","journal-title":"Neurology"},{"key":"558_CR20","first-page":"e1816","volume":"95","author":"P Iaffaldano","year":"2020","unstructured":"Iaffaldano P, Viterbo RG, Portaccio E, et al. Natalizumab discontinuation and rebound risk in multiple sclerosis. Neurology. 2020;95:e1816\u201326.","journal-title":"Neurology"},{"key":"558_CR21","doi-asserted-by":"publisher","unstructured":"Chisari CG, Lo Fermo S, Iacono S, Schir\u00f2 G, Ruscica F, Realmuto S, et al. Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: insights from na\u00efve and switch patients. Neurotherapeutics. 2025;22(6):e00724. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00724.","DOI":"10.1016\/j.neurot.2025.e00724"},{"key":"558_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","volume":"15","author":"M Amin","year":"2025","unstructured":"Amin M, Harvey T, Pineda DM, et al. Real-world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Neurodegener Dis Manag. 2025;15:27\u201336.","journal-title":"Neurodegener Dis Manag"},{"key":"558_CR23","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s40120-025-00818-7","volume":"14","author":"G Ferrazzano","year":"2025","unstructured":"Ferrazzano G, Fantozzi R, Haggiag S, et al. Real-world 24-month outcomes of ofatumumab in relapsing multiple sclerosis. Neurol Ther. 2025;14:2313\u201325.","journal-title":"Neurol Ther"},{"issue":"7","key":"558_CR24","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00415-024-12360-x","volume":"271","author":"A Zangh\u00ec","year":"2024","unstructured":"Zangh\u00ec A, Borriello G, Bonavita S, et al. Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study. J Neurol. 2024;271(7):4495\u2013502.","journal-title":"J Neurol"},{"issue":"1","key":"558_CR25","volume":"12","author":"T Montague","year":"2026","unstructured":"Montague T, Cheung E, Kang Y, et al. Real-world safety and effectiveness of ofatumumab in multiple sclerosis: a clinic-based study in Australia. Mult Scler J Exp Transl Clin. 2026;12(1):20552173251414528.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"9","key":"558_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091568","volume":"61","author":"W Galus","year":"2025","unstructured":"Galus W, Kaczmarczyk A, Walawska-Hrycek A, et al. Real-world data of first 12-months of ofatumumab treatment in multiple sclerosis patients\u2014a multicenter experience from tertiary referral centers. Medicina B Aires. 2025;61(9):1568.","journal-title":"Medicina B Aires"},{"key":"558_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104881","volume":"78","author":"PK Coyle","year":"2023","unstructured":"Coyle PK, Gorritz M, Wade RL, et al. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during the COVID-19 pandemic. Mult Scler Relat Disord. 2023;78:104881.","journal-title":"Mult Scler Relat Disord"},{"key":"558_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373.","journal-title":"Lancet Neurol"},{"issue":"8","key":"558_CR29","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, et al. Evidence-based guidelines: MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653\u201370.","journal-title":"Lancet Neurol"},{"key":"558_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, et al. No evidence of disease activity (NEDA): concepts and implications. Mult Scler. 2017;23:1179\u201387.","journal-title":"Mult Scler"},{"key":"558_CR31","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/ene.15406","volume":"29","author":"S Sharmin","year":"2022","unstructured":"Sharmin S, Bovis F, Malpas C, et al. Confirmed disability progression as a surrogate outcome in multiple sclerosis. Eur J Neurol. 2022;29:2321\u201334.","journal-title":"Eur J Neurol"},{"key":"558_CR32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneurol.2013.146","volume":"9","author":"MP Sormani","year":"2013","unstructured":"Sormani MP, De Stefano N. MRI markers of disease evolution in multiple sclerosis. Nat Rev Neurol. 2013;9:327\u201338.","journal-title":"Nat Rev Neurol"},{"key":"558_CR33","doi-asserted-by":"crossref","first-page":"e2101","DOI":"10.1212\/WNL.94.15_supplement.2101","volume":"94","author":"L Kappos","year":"2020","unstructured":"Kappos L, Butzkueven H, Wiendl H, et al. Disability improvement in relapsing multiple sclerosis patients treated with ocrelizumab. Neurology. 2020;94:e2101\u201314.","journal-title":"Neurology"},{"issue":"2","key":"558_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2020;77(2):184\u201391.","journal-title":"JAMA Neurol"},{"key":"558_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200349","volume":"12","author":"S Vukusic","year":"2025","unstructured":"Vukusic S, Bove R, Dobson R, et al. Pregnancy and infant outcomes in women with multiple sclerosis treated with ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200349.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"558_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515730","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Wu Y, Zhao X, et al. The real-world safety of ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system. Front Immunol. 2025;16:1515730.","journal-title":"Front Immunol"},{"key":"558_CR37","first-page":"1507","volume":"78","author":"L Zhovtis Ryerson","year":"2021","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, et al. Hypogammaglobulinemia and infectious risk in multiple sclerosis patients treated with anti-CD20 therapies. JAMA Neurol. 2021;78:1507\u201317.","journal-title":"JAMA Neurol"},{"key":"558_CR38","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1212\/WNL.0000000000202006","volume":"100","author":"LZ Ryerson","year":"2023","unstructured":"Ryerson LZ, Foley J, Chang I, et al. Risk of infections in patients receiving anti-CD20 therapies for multiple sclerosis. Neurology. 2023;100:e1239\u201350.","journal-title":"Neurology"},{"key":"558_CR39","volume":"80","author":"D Baroncini","year":"2024","unstructured":"Baroncini D, Moiola L, Annovazzi P, et al. Switching from high-efficacy therapies to anti-CD20 monoclonal antibodies: safety considerations in clinical practice. Mult Scler Relat Disord. 2024;80:104961.","journal-title":"Mult Scler Relat Disord"},{"key":"558_CR40","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200410","volume":"15","author":"S Hefner","year":"2025","unstructured":"Hefner S, Casaccia TL, Hofstaetter E, et al. Impact of continuous ofatumumab exposure during pregnancy in multiple sclerosis. Neurol Clin Pract. 2025;15:e200410.","journal-title":"Neurol Clin Pract"},{"key":"558_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/pn-2022-003426","volume":"23","author":"R Dobson","year":"2023","unstructured":"Dobson R, Rog D, Ovadia C, et al. Anti-CD20 therapies in pregnancy and breastfeeding: a review and ABN guidelines. Pract Neurol. 2023;23:6\u201314.","journal-title":"Pract Neurol"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00558-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00558-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:33Z","timestamp":1782098373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00558-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,31]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00558-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,31]]},"assertion":[{"value":"7 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vincenzo Mangialardi, Giuseppe Macchitella, Rita Vitobello, Antonella Teofilo, Nicola Cavalli, Caterina Lapucci, and Elisa Idini declare no competing financial or non-financial interests related to the content of this article. Jessica Frau reports relationships with Biogen, Bristol Myers Squibb, Novartis, Sanofi-Genzyme, Merck, Teva, and Alexion, including advisory board participation, consultancy activities, and speaker honoraria. Pietro Iaffaldano has received honoraria for lecturing, participation in advisory boards, and\/or travel expenses for attending congresses and meetings from Almirall, Biogen Idec, Merck Serono, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. Paola Cavalla has received honoraria for consultancy or speaking activities from Alexion, Biogen, Bristol Myers Squibb, Merck, Novartis, Sanofi, and Roche. Maria Matilde Inglese has received personal compensation for consulting, serving on scientific advisory boards, or speaking activities from Alexion, Biogen, Bristol Myers Squibb, Janssen, Merck, Novartis, Roche, and Sanofi-Genzyme. Eleonora Cocco has received honoraria for consultancy or speaking activities from Bayer, Biogen, Novartis, Sanofi, Merck, Teva, Roche, Bristol Myers Squibb, Janssen, and Alexion. Damiano Paolicelli has received honoraria for advisory board membership and speaking activities, travel support, research grants, consulting fees, or clinical trial support from Biogen, Bristol Myers Squibb\u2013Celgene, Sanofi-Genzyme, Merck, Novartis, and Roche. All declared interests are unrelated to the conduct and reporting of the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective multicenter study was conducted in accordance with the ethical standards of the institutional and national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments. This study protocol was approved by the Local Ethics Committee of the University of Bari \u2018Aldo Moro\u2019 (Comitato Etico Territoriale AOU Consorziale Policlinico di Bari) and by the Ethics Committees of the participating centers. Ethical approval was obtained at each participating center in accordance with national regulations for retrospective studies. This was a retrospective observational study and therefore did not require prospective trial registration.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent to participate in the study was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable. The manuscript does not contain identifiable individual data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to data protection and privacy regulations but are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Damiano Paolicelli contributed to the study concept and design. Vincenzo Mangialardi and Giuseppe Macchitella contributed to the analysis and interpretation of the data and drafted the manuscript. Rita Vitobello, Antonella Teofilo, Nicola Cavalli, Caterina Lapucci, Marco Vercellino, Elisa Idini, Jessica Frau, Pietro Iaffaldano, Paola Cavalla, Maria Matilde Inglese, and Eleonora Cocco contributed to data acquisition and interpretation and critically revised the manuscript for important intellectual content. All authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}